Clinical trial
Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
NCT03715959 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 10, 2020
- Completion date
- January 1, 2024
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, estrogen receptor negative, healthy subject, her2 positive breast carcinoma, her2/neu negative, luminal a breast carcinoma, luminal b breast carcinoma, progesterone receptor negative, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, prognostic stage iv breast cancer ajcc v8, triple-negative breast carcinoma